

National Library DuhMed

	OI	or Medicine Luu				J	
PubMed	Nucleotide	Protein	Genome	Structure	PopSet	Taxonomy	OMIM
Search Publ	Med 🔽 for					Go Cle	
	Limit	s Previe	w/Index Hi	story Clip	board		
	j _E	-	-				
Entrez PubM	Display	Abstract	▼ Save	Text Ord	ler Addit	o Clipboard	
LIMIGZ FUDIVI			164000 - 4				
	II: Pro	receivers.	urif 1997 Feb	9(1):33-9	Rela	ated Articles, Bo	oks, LinkOut
	Higl	h-level exi	nression an	d nurificat	ion of the r	majar hirah	nallan

PubMed Services

el expression and purification of the major birch pollen allergen, Bet v 1.

Hoffmann-Sommergruber K, Susani M, Ferreira F, Jertschin P, Ahorn H, Steiner R, Kraft D, Scheiner O, Breiteneder H

Institute of General and Experimental Pathology, University of Vienna, Austria.

Related Resources

Bet v 1, the single major allergen from birch pollen, shares IgE epitopes with all major tree pollen allergens from closely related species such as alder, hazel, hornbeam, beech, and European chestnut. Because of high sequence homologies among these allergens and the well-studied cross-reactivities on B cell epitopes, Bet v 1 is a representative model protein which can be used for in vitro studies. The cDNA coding for Bet v 1, the single major allergen from birch pollen, was cloned into the T7-based Escherichia coli expression system pMW 175/BL21(DE3) and synthesized as a nonfusion protein. In contrast to other E. coli systems (e.g., pKK233-2/JM105), this system produces high levels of readily extractable proteins corresponding to 5-10% of E. coli total protein, the percentage varying with culture conditions. The overall yield was 8-10 mg of purified recombinant protein per liter of culture medium. The recombinant allergen was purified by several steps, including ion-exchange and hydrophobic interaction chromatography. The purified recombinant allergen showed identical immunological properties with the respective natural counterpart. The use of recombinant allergens of high purity is expected to result in more accurate diagnostic procedures, but possibly also in a superior immunotherapy of Type I allergic diseases when compared with methods using crude allergen extracts containing various amounts of allergen concentrations.

PMID: 9116499, UI: 97177234

Write to the Help Desk NCBI | NLM | NIH